TD Cowen initiated coverage of Freenome with a Buy rating and a $17 price target, citing the company’s liquid biopsy chemistry and commercial partnerships with Abbott and Roche. The analyst pointed to a sales ramp tied to multi-cancer early detection (MCED) and single-cancer screening assays, anchored by a colorectal cancer product previously commercialized through Abbott. The note flags execution risks including cash burn, projected large capital needs and uncertainty around pipeline visibility beyond early CRC success. Still, it argues Freenome has differentiated assay chemistry and an opportunity to expand uptake through add-on testing when clinicians prescribe CRC screening. For investors and liquid biopsy competitors, the coverage reiterates how partnership-led commercialization and near-term assay expansion remain central to market narratives in blood-based cancer screening.